Wilhelmina Childrens Hospital
- Address
- Lundlaan 6, 3584 EA Utrecht, The Netherlands
Wilhelmina Children's Hospital - Pediatric Immunology and Rheumatology Center
Wilhelmina Children's Hospital is a leading pediatric research center with distinguished expertise in autoimmune and inflammatory conditions affecting children. The center demonstrates particular strength in rare disease research and novel therapeutic approaches for complex pediatric rheumatologic disorders.
- Juvenile Idiopathic Arthritis subtypes including systemic JIA, enthesitis-related arthritis, and juvenile psoriatic arthritis
- Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
- Rare genetic disorders including Alagille Syndrome and GRIN-related neurological disorders
- Inflammatory bowel disease including Crohn's Disease in pediatric populations
The hospital conducts innovative research in biomarker-guided treatment strategies and personalized medicine approaches, particularly focusing on optimizing biologic therapies and targeted treatments. Their comprehensive portfolio includes studies evaluating novel immunomodulatory agents such as emapalumab, ixekizumab, and apremilast, as well as investigating pharmacokinetic profiles and dose optimization in pediatric patients. The center's commitment to advancing care for children with rare and life-threatening conditions positions it at the forefront of pediatric immunology and rheumatology research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 10 of 11 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Longboard Pharmaceuticals Inc.1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Longboard Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Wilhelmina Childrens Hospital
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Biomarker-Guided Anakinra Tapering Strategy in Pediatric Systemic Juvenile Idiopathic Arthritis: A Randomized Controlled Trial | Universitair Medisch Centrum Utrecht | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2021-02-22 | 2021-02-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.